IDH1 and glioma: Thus, the distribution of cell nanomechanical properties may serve as the detailed diagnostic criteria for glioma clinical outcomes; assuming that CD44-/IDH1 wild-type cells display the lowest stiffness, CD44+/IDH1 wild-type are characterized by the moderate stiffness, and the IDH1 R132H mutant cell population is the stiffest one, mainly comprising CD44+ cells.